Real life experience with nivolumab for the treatment of non-small cell lung carcinoma: Data from the expanded access program and routine clinical care in a tertiary cancer centre-The Netherlands Cancer Institute

Robert D Schouten; Mirte Muller; Cornedine J de Gooijer; Paul Baas; Michel van den Heuvel

doi:10.1016/j.lungcan.2017.11.012

Real life experience with nivolumab for the treatment of non-small cell lung carcinoma: Data from the expanded access program and routine clinical care in a tertiary cancer centre-The Netherlands Cancer Institute

Robert D Schouten
, Mirte Muller
, Cornedine J de Gooijer
, Paul Baas
, Michel van den Heuvel

Research output: Contribution to journal › Article › Academic › peer-review

Original language	English
Pages (from-to)	210-216
Number of pages	7
Journal	Lung Cancer
Volume	126
DOIs	https://doi.org/10.1016/j.lungcan.2017.11.012
Publication status	Published - Dec 2018
Externally published	Yes

Keywords

Adult
Aged
Antineoplastic Agents, Immunological/adverse effects
Carcinoma, Non-Small-Cell Lung/drug therapy
Female
Humans
Hypothyroidism/chemically induced
Kaplan-Meier Estimate
Lung Neoplasms/drug therapy
Male
Middle Aged
Netherlands
Nivolumab/adverse effects
Tertiary Care Centers

Access to Document

10.1016/j.lungcan.2017.11.012

Cite this

Schouten, R. D., Muller, M., de Gooijer, C. J., Baas, P., & van den Heuvel, M. (2018). Real life experience with nivolumab for the treatment of non-small cell lung carcinoma: Data from the expanded access program and routine clinical care in a tertiary cancer centre-The Netherlands Cancer Institute. Lung Cancer, 126, 210-216. https://doi.org/10.1016/j.lungcan.2017.11.012

@article{ddf73723b4b24b7baec492cff709fd6b,

title = "Real life experience with nivolumab for the treatment of non-small cell lung carcinoma: Data from the expanded access program and routine clinical care in a tertiary cancer centre-The Netherlands Cancer Institute",

keywords = "Adult, Aged, Antineoplastic Agents, Immunological/adverse effects, Carcinoma, Non-Small-Cell Lung/drug therapy, Female, Humans, Hypothyroidism/chemically induced, Kaplan-Meier Estimate, Lung Neoplasms/drug therapy, Male, Middle Aged, Netherlands, Nivolumab/adverse effects, Tertiary Care Centers",

author = "Schouten, \{Robert D\} and Mirte Muller and \{de Gooijer\}, \{Cornedine J\} and Paul Baas and \{van den Heuvel\}, Michel",

year = "2018",

month = dec,

doi = "10.1016/j.lungcan.2017.11.012",

language = "English",

volume = "126",

pages = "210--216",

journal = "Lung Cancer",

issn = "0169-5002",

publisher = "Elsevier Ireland Ltd",

}

Schouten, RD, Muller, M, de Gooijer, CJ, Baas, P & van den Heuvel, M 2018, 'Real life experience with nivolumab for the treatment of non-small cell lung carcinoma: Data from the expanded access program and routine clinical care in a tertiary cancer centre-The Netherlands Cancer Institute', Lung Cancer, vol. 126, pp. 210-216. https://doi.org/10.1016/j.lungcan.2017.11.012

Real life experience with nivolumab for the treatment of non-small cell lung carcinoma: Data from the expanded access program and routine clinical care in a tertiary cancer centre-The Netherlands Cancer Institute. / Schouten, Robert D; Muller, Mirte; de Gooijer, Cornedine J et al.
In: Lung Cancer, Vol. 126, 12.2018, p. 210-216.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Real life experience with nivolumab for the treatment of non-small cell lung carcinoma

T2 - Data from the expanded access program and routine clinical care in a tertiary cancer centre-The Netherlands Cancer Institute

AU - Schouten, Robert D

AU - Muller, Mirte

AU - de Gooijer, Cornedine J

AU - Baas, Paul

AU - van den Heuvel, Michel

PY - 2018/12

Y1 - 2018/12

KW - Adult

KW - Aged

KW - Antineoplastic Agents, Immunological/adverse effects

KW - Carcinoma, Non-Small-Cell Lung/drug therapy

KW - Female

KW - Humans

KW - Hypothyroidism/chemically induced

KW - Kaplan-Meier Estimate

KW - Lung Neoplasms/drug therapy

KW - Male

KW - Middle Aged

KW - Netherlands

KW - Nivolumab/adverse effects

KW - Tertiary Care Centers

U2 - 10.1016/j.lungcan.2017.11.012

DO - 10.1016/j.lungcan.2017.11.012

M3 - Article

C2 - 29179916

SN - 0169-5002

VL - 126

SP - 210

EP - 216

JO - Lung Cancer

JF - Lung Cancer

ER -